{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:00:27Z","timestamp":1794603627824,"version":"4.9.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF22OC0076055"],"award-info":[{"award-number":["NNF22OC0076055"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF23SA0087869"],"award-info":[{"award-number":["NNF23SA0087869"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF23OC0086106"],"award-info":[{"award-number":["NNF23OC0086106"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004376","name":"Terry Fox Research Institute","doi-asserted-by":"publisher","award":["1109"],"award-info":[{"award-number":["1109"]}],"id":[{"id":"10.13039\/501100004376","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Antibody-drug conjugates (ADC) offer a targeted cancer treatment approach by delivering cytotoxic payloads directly to tumor cells. However, resistance mechanisms, poor tumor penetration, and off-target toxicity often limit clinical efficacy. Vartumab targets oncofetal chondroitin sulfate (ofCS), a pan-cancer target present on tumor cells and in the malignant stroma, with low expression in normal tissues. As part of transitioning Vartumab to clinical evaluation, two linker-payloads known to mediate bystander effects, valine-citrulline (vc)\u2014monomethyl auristatin E (MMAE) and glycine-glycine-phenylalanine-glycine (ggfg)\u2014Deruxtecan (DXd), were investigated for design of Vartumab ADCs. We show that the ADCs maintain specificity to ofCS proteoglycans, cancer cells, and tissue biopsies, exhibiting specific binding to a wide range of malignant and metastatic tissues. Biodistribution assessment of Vartumab ADCs in mice shows strong and specific tumor uptake, with minimal accumulation in other organs. Both ADCs induced bystander killing of antigen-negative cells in the presence of antigen-positive cells and displayed potent anti-tumor activities in a cell-derived xenograft melanoma model. Furthermore, we show that Vartumab conjugates with bystander-capable linker-payloads exhibit greater in vivo potency compared to those with payloads lacking significant bystander effect. Finally, toxicity assessment in rats indicates that the ADC-MMAE is well-tolerated upon repeated doses, with similar dose-limiting toxicities as reported for clinically approved MMAE-conjugated ADCs. Our data support further clinical development of Vartumab-based ADCs.<\/jats:p>","DOI":"10.1038\/s41419-026-08420-x","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T22:35:19Z","timestamp":1769294119000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Preclinical profiling of antibody drug conjugates targeting oncofetal chondroitin sulfate"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1024-2224","authenticated-orcid":false,"given":"Ann","family":"Skafte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9655-2106","authenticated-orcid":false,"given":"Elena Ethel","family":"Vidal-Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Mujollari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5594-0716","authenticated-orcid":false,"given":"Robert","family":"Dagil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Martin-Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8514-2713","authenticated-orcid":false,"given":"Htoo Zarni","family":"Oo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4540-3764","authenticated-orcid":false,"given":"Lara","family":"Duvnjak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thor G.","family":"Theander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Daugaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0243-2248","authenticated-orcid":false,"given":"Tobias","family":"Gustavsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2207-5575","authenticated-orcid":false,"given":"Ali","family":"Salanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"key":"8420_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA A Cancer J Clin"},{"key":"8420_CR2","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/s41417-021-00333-5","volume":"28","author":"C Garc\u00eda-Fern\u00e1ndez","year":"2021","unstructured":"Garc\u00eda-Fern\u00e1ndez C, Saz A, Fornaguera C, Borr\u00f3s S. Cancer immunotherapies revisited: state of the art of conventional treatments and next-generation nanomedicines. Cancer Gene Ther. 2021;28:935\u201346.","journal-title":"Cancer Gene Ther"},{"key":"8420_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12652-5","volume":"24","author":"W Zhou","year":"2024","unstructured":"Zhou W, Xu Z, Liu S, Lou X, Liu P, Xie H, et al. Landscape of clinical drug development of ADCs used for the pharmacotherapy of cancers: an overview of clinical trial registry data from 2002 to 2022. BMC Cancer. 2024;24:898.","journal-title":"BMC Cancer"},{"key":"8420_CR4","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/cancers15030713","volume":"15","author":"TD Nguyen","year":"2023","unstructured":"Nguyen TD, Bordeau BM, Balthasar JP. Mechanisms of ADC toxicity and strategies to increase ADC tolerability. Cancers. Cancers. 2023;15:713","journal-title":"Cancers"},{"key":"8420_CR5","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.3390\/ijms24119674","volume":"24","author":"R Khoury","year":"2023","unstructured":"Khoury R, Saleh K, Khalife N, Saleh M, Chahine C, Ibrahim R. et al. Mechanisms of resistance to antibody-drug conjugates. Int J Mol Sci. 2023;24:1278","journal-title":"Int J Mol Sci"},{"key":"8420_CR6","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/clpt.2014.105","volume":"96","author":"I Fuso Nerini","year":"2014","unstructured":"Fuso Nerini I, Morosi L, Zucchetti M, Ballerini A, Giavazzi R, D\u2019Incalci M. Intratumor heterogeneity and its impact on drug distribution and sensitivity. Clin Pharmacol Ther. 2014;96:224\u201338.","journal-title":"Clin Pharmacol Ther"},{"key":"8420_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102720","volume":"125","author":"RS Heist","year":"2024","unstructured":"Heist RS, Sands J, Bardia A, Shimizu T, Lisberg A, Krop I, et al. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev. 2024;125:102720.","journal-title":"Cancer Treat Rev"},{"key":"8420_CR8","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1369\/0022155411410430","volume":"59","author":"LP Stepan","year":"2011","unstructured":"Stepan LP, Trueblood ES, Hale K, Babcook J, Borges L, Sutherland CL. Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. J Histochem Cytochem. 2011;59:701\u201310.","journal-title":"J Histochem Cytochem"},{"key":"8420_CR9","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa1814213","volume":"380","author":"A Bardia","year":"2019","unstructured":"Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, et al. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2019;380:741\u201351.","journal-title":"N Engl J Med"},{"key":"8420_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7827-8-133","volume":"8","author":"DM Baston-Bust","year":"2010","unstructured":"Baston-Bust DM, Gotte M, Janni W, Krussel JS, Hess AP. Syndecan-1 knock-down in decidualized human endometrial stromal cells leads to significant changes in cytokine and angiogenic factor expression patterns. Reprod Biol Endocrinol. 2010;8:133.","journal-title":"Reprod Biol Endocrinol"},{"key":"8420_CR11","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.addr.2011.12.010","volume":"64","author":"Y Matsumura","year":"2012","unstructured":"Matsumura Y. Cancer stromal targeting (CAST) therapy. Adv Drug Deliv Rev. 2012;64:710\u20139.","journal-title":"Adv Drug Deliv Rev"},{"key":"8420_CR12","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, Saura C, Yamashita T, Park YH, Kim S-B, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382:610\u201321.","journal-title":"N Engl J Med"},{"key":"8420_CR13","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/cas.12966","volume":"107","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107:1039\u201346.","journal-title":"Cancer Sci"},{"key":"8420_CR14","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","volume":"24","author":"F Giugliano","year":"2022","unstructured":"Giugliano F, Corti C, Tarantino P, Michelini F, Curigliano G. Bystander effect of antibody-drug conjugates: fact or fiction? Curr Oncol Rep. 2022;24:809\u201317.","journal-title":"Curr Oncol Rep"},{"key":"8420_CR15","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","volume":"13","author":"Z Wang","year":"2023","unstructured":"Wang Z, Li H, Gou L, Li W, Wang Y. Antibody-drug conjugates: Recent advances in payloads. Acta Pharmaceutica Sin B. 2023;13:4025\u201359.","journal-title":"Acta Pharmaceutica Sin B"},{"key":"8420_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01670-1","volume":"21","author":"M Xu","year":"2022","unstructured":"Xu M, Zhang T, Xia R, Wei Y, Wei X. Targeting the tumor stroma for cancer therapy. Mol Cancer. 2022;21:208.","journal-title":"Mol Cancer"},{"key":"8420_CR17","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/cas.12062","volume":"104","author":"M Yasunaga","year":"2013","unstructured":"Yasunaga M, Manabe S, Tarin D, Matsumura Y. Tailored immunoconjugate therapy depending on a quantity of tumor stroma. Cancer Sci. 2013;104:231\u20137.","journal-title":"Cancer Sci"},{"key":"8420_CR18","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cortes","year":"2022","unstructured":"Cortes J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386:1143\u201354.","journal-title":"N Engl J Med"},{"key":"8420_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58266-8","volume":"16","author":"LC Tsao","year":"2025","unstructured":"Tsao LC, Wang JS, Ma X, Sodhi S, Ragusa JV, Liu B, et al. Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd). Nat Commun. 2025;16:3167.","journal-title":"Nat Commun"},{"key":"8420_CR20","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.ccell.2015.09.003","volume":"28","author":"A Salanti","year":"2015","unstructured":"Salanti A, Clausen TM, Agerb\u00e6k MO, Al Nakouzi N, Dahlb\u00e4ck M, Oo HZ. et al. Targeting human cancer by a glycosaminoglycan-binding malaria protein. Cancer Cell. 2015;28:500\u201314.","journal-title":"Cancer Cell"},{"key":"8420_CR21","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/bjc.1996.362","volume":"74","author":"J Dancey","year":"1996","unstructured":"Dancey J, Eisenhauer EA. Current perspectives on camptothecins in cancer treatment. Br J Cancer. 1996;74:327\u201338.","journal-title":"Br J Cancer"},{"key":"8420_CR22","doi-asserted-by":"crossref","unstructured":"Diamantis N, Banerji U. Antibody-drug conjugated-an emerging class of cancer treatment. Br J Cancer. 2016;114:362\u20137.","DOI":"10.1038\/bjc.2015.435"},{"key":"8420_CR23","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0925-4439(00)00051-X","volume":"1502","author":"AD Theocharis","year":"2000","unstructured":"Theocharis AD, Tsara ME, Papageorgacopoulou N, Karavias DD, Theocharis DA. Pancreatic carcinoma is characterized by elevated content of hyaluronan and chondroitin sulfate with altered disaccharide composition. Biochim Biophys Acta. 2000;1502:201\u20136.","journal-title":"Biochim Biophys Acta"},{"key":"8420_CR24","first-page":"363","volume":"4","author":"D Kalathas","year":"2011","unstructured":"Kalathas D, Theocharis DA, Bounias D, Kyriakopoulou D, Papageorgakopoulou N, Stavropoulos MS, et al. Chondroitin synthases I, II, III and chondroitin sulfate glucuronyltransferase expression in colorectal cancer. Mol Med Rep. 2011;4:363\u20138.","journal-title":"Mol Med Rep"},{"key":"8420_CR25","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1095\/biolreprod67.2.681","volume":"67","author":"G Xu","year":"2002","unstructured":"Xu G, Guimond MJ, Chakraborty C, Lala PK. Control of proliferation, migration, and invasiveness of human extravillous trophoblast by decorin, a decidual product. Biol Reprod. 2002;67:681\u20139.","journal-title":"Biol Reprod"},{"key":"8420_CR26","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1084\/jem.20041579","volume":"200","author":"A Salanti","year":"2004","unstructured":"Salanti A, Dahlb\u201eck M, Turner L, Nielsen MA, Barfod L, Magistrado P. Evidence for the involvement of VAR2CSA in pregnancy-associated malaria. J Exp Med. 2004;200:1197\u2013203.","journal-title":"J Exp Med"},{"key":"8420_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05793-2","volume":"9","author":"MO Agerbaek","year":"2018","unstructured":"Agerbaek MO, Bang-Christensen SR, Yang MH, Clausen TM, Pereira MA, Sharma S, et al. The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAM-independent manner. Nat Commun. 2018;9:3279.","journal-title":"Nat Commun"},{"key":"8420_CR28","doi-asserted-by":"publisher","first-page":"101391","DOI":"10.1016\/j.jbc.2021.101391","volume":"297","author":"CB Spliid","year":"2021","unstructured":"Spliid CB, Toledo AG, Sanderson P, Mao Y, Gatto F, Gustavsson T. et al. The specificity of the malarial VAR2CSA protein for chondroitin sulfate depends on 4-O-sulfation and ligand accessibility. J Biol Chem. 2021;297:101391","journal-title":"J Biol Chem"},{"key":"8420_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51781-0","volume":"15","author":"EE Vidal-Calvo","year":"2024","unstructured":"Vidal-Calvo EE, Martin-Salazar A, Choudhary S, Dagil R, Raghavan SSR, Duvnjak L, et al. Tumor-agnostic cancer therapy using antibodies targeting oncofetal chondroitin sulfate. Nat Commun. 2024;15:7553.","journal-title":"Nat Commun"},{"key":"8420_CR30","doi-asserted-by":"publisher","first-page":"e5209","DOI":"10.1371\/journal.pone.0005209","volume":"4","author":"DA Bax","year":"2009","unstructured":"Bax DA, Little SE, Gaspar N, Perryman L, Marshall L, Viana-Pereira M, et al. Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development. PLoS ONE. 2009;4:e5209.","journal-title":"PLoS ONE"},{"key":"8420_CR31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1208\/s12248-022-00720-2","volume":"24","author":"B Yao","year":"2022","unstructured":"Yao B, Gao X, Dan M, Yuan C, Hu X, Sun Z, et al. Selection of payloads for antibody-drug conjugates targeting ubiquitously expressed tumor-associated antigens: a case study. AAPS J. 2022;24:70.","journal-title":"AAPS J"},{"key":"8420_CR32","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1248\/cpb.c18-00744","volume":"67","author":"T Nakada","year":"2019","unstructured":"Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. Chem Pharm Bull. 2019;67:173\u201385.","journal-title":"Chem Pharm Bull"},{"key":"8420_CR33","doi-asserted-by":"publisher","first-page":"7027","DOI":"10.1158\/0008-5472.CAN-17-2391","volume":"77","author":"NG Caculitan","year":"2017","unstructured":"Caculitan NG, Dela Cruz Chuh J, Ma Y, Zhang D, Kozak KR, Liu Y, et al. Cathepsin B is dispensable for cellular processing of cathepsin B-cleavable antibody-drug conjugates. Cancer Res. 2017;77:7027\u201337.","journal-title":"Cancer Res"},{"key":"8420_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmd.2025.100081","volume":"53","author":"Z Li","year":"2025","unstructured":"Li Z, Zhang J, Wu Y, Wang F, Cai T. Integrated strategy for biotransformation of antibody-drug conjugates and multidimensional interpretation via high-resolution mass spectrometry. Drug Metab Dispos. 2025;53:100081.","journal-title":"Drug Metab Dispos"},{"key":"8420_CR35","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.3390\/biomedicines11113080","volume":"11","author":"S Balamkundu","year":"2023","unstructured":"Balamkundu S, Liu CF. Lysosomal-cleavable peptide linkers in antibody-drug conjugates. Biomedicines. 2023;11:3080","journal-title":"Biomedicines"},{"key":"8420_CR36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ddtec.2018.07.002","volume":"30","author":"PA Szijj","year":"2018","unstructured":"Szijj PA, Bahou C, Chudasama V. Minireview: addressing the retro-Michael instability of maleimide bioconjugates. Drug Discov Today Technol. 2018;30:27\u201334.","journal-title":"Drug Discov Today Technol"},{"key":"8420_CR37","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1021\/acs.molpharmaceut.8b00177","volume":"15","author":"JW Buecheler","year":"2018","unstructured":"Buecheler JW, Winzer M, Tonillo J, Weber C, Gieseler H. Impact of payload hydrophobicity on the stability of antibody-drug conjugates. Mol Pharm. 2018;15:2656\u201364.","journal-title":"Mol Pharm"},{"key":"8420_CR38","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/(SICI)1097-4598(199908)22:8<1119::AID-MUS16>3.0.CO;2-S","volume":"22","author":"M Yerroum","year":"1999","unstructured":"Yerroum M, Braconnier F, Chariot P. Influence of handling procedures on rat plasma creatine kinase activity. Muscle Nerve. 1999;22:1119\u201321.","journal-title":"Muscle Nerve"},{"key":"8420_CR39","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1021\/acs.molpharmaceut.0c00873","volume":"18","author":"DV Nadkarni","year":"2021","unstructured":"Nadkarni DV, Lee J, Jiang Q, Patel V, Sriskanda V, Dutta K, et al. Impact of drug conjugation and loading on target antigen binding and cytotoxicity in cysteine antibody-drug conjugates. Mol Pharm. 2021;18:889\u201397.","journal-title":"Mol Pharm"},{"key":"8420_CR40","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1158\/0008-5472.CAN-15-1795","volume":"76","author":"F Li","year":"2016","unstructured":"Li F, Emmerton KK, Jonas M, Zhang X, Miyamoto JB, Setter JR, et al. Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models. Cancer Res. 2016;76:2710\u20139.","journal-title":"Cancer Res"},{"key":"8420_CR41","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1080\/00498254.2020.1755909","volume":"50","author":"H Okamoto","year":"2020","unstructured":"Okamoto H, Oitate M, Hagihara K, Shiozawa H, Furuta Y, Ogitani Y, et al. Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice. Xenobiotica. 2020;50:1242\u201350.","journal-title":"Xenobiotica"},{"key":"8420_CR42","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.jconrel.2024.02.014","volume":"367","author":"M Bocci","year":"2024","unstructured":"Bocci M, Zana A, Principi L, Lucaroni L, Prati L, Gilardoni E, et al. In vivo activation of FAP-cleavable small molecule-drug conjugates for the targeted delivery of camptothecins and tubulin poisons to the tumor microenvironment. J Control Release. 2024;367:779\u201390.","journal-title":"J Control Release"},{"key":"8420_CR43","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.1111\/cas.16335","volume":"115","author":"R Tsumura","year":"2024","unstructured":"Tsumura R, Anzai T, Koga Y, Takashima H, Matsumura Y, Yasunaga M. Anti-tissue factor antibody conjugated with monomethyl auristatin E or deruxtecan in pancreatic cancer models. Cancer Sci. 2024;115:3986\u201396.","journal-title":"Cancer Sci"},{"key":"8420_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107272","volume":"26","author":"P Zhang","year":"2023","unstructured":"Zhang P, Tao C, Shimura T, Huang AC, Kong N, Dai Y, et al. ICAM1 antibody drug conjugates exert potent antitumor activity in papillary and anaplastic thyroid carcinoma. iScience. 2023;26:107272.","journal-title":"iScience"},{"key":"8420_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00447-z","volume":"7","author":"B Zhu","year":"2023","unstructured":"Zhu B, Wang X, Shimura T, Huang AC, Kong N, Dai Y, et al. Development of potent antibody drug conjugates against ICAM1(+) cancer cells in preclinical models of cholangiocarcinoma. NPJ Precis Oncol. 2023;7:93.","journal-title":"NPJ Precis Oncol"},{"key":"8420_CR46","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.ccell.2022.09.016","volume":"40","author":"R Colombo","year":"2022","unstructured":"Colombo R, Rich JR. The therapeutic window of antibody drug conjugates: a dogma in need of revision. Cancer Cell. 2022;40:1255\u201363.","journal-title":"Cancer Cell"},{"key":"8420_CR47","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","volume":"14","author":"R Colombo","year":"2024","unstructured":"Colombo R, Tarantino P, Rich JR, LoRusso PM, de Vries EGE. The journey of antibody-drug conjugates: lessons learned from 40 years of development. Cancer Discov. 2024;14:2089\u2013108.","journal-title":"Cancer Discov"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08420-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08420-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08420-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T15:03:53Z","timestamp":1770303833000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08420-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8420"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08420-x","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,24]]},"assertion":[{"value":"14 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ASa, MD, and TGT are shareholders of VAR2 Pharmaceuticals. The antibodies are subject to a patenting process owned by VAR2 Pharmaceuticals. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"162"}}